China biopharma – Charting a path to value creation

For nine years, the China Healthcare Summit has focused on building a "Bridge to Innovation" in China. But now, the foundational pillars of China's innovation ecosystem are challenged: COVID, geopolitics, an extended bear market, significant pricing pressure. For its 10th China Summit report, McKinsey & Company takes stock of the China biopharma industry's progress on value creation and decodes how it can create a sustainable impact on the global biopharma industry.